Status:

COMPLETED

Intravenous Magnesium Sulfate in Aneurysmal Subarachnoid Haemorrhage (IMASH)

Lead Sponsor:

Chinese University of Hong Kong

Conditions:

Subarachnoid Hemorrhage

Eligibility:

All Genders

18-80 years

Phase:

PHASE3

Brief Summary

The IMASH trial is a simple, randomized, double-blinded, placebo-controlled, multi-center trial to answer the question: "Does intravenous magnesium sulfate improve clinical outcome after aneurysmal su...

Detailed Description

Vasospasm worsen outcome in patients with aneurysmal subarachnoid hemorrhage (ASAH). Magnesium is known to dilate cerebral arteries and to block N-methyl-D-aspartate receptors in the injured neurons....

Eligibility Criteria

Inclusion

  • ASAH (as indicated by CT scan or lumbar puncture and an intracranial aneurysm confirmed by computer tomographic or conventional angiography)
  • Within 48 hrs of ictus (hemorrhage event)

Exclusion

  • Pregnancy
  • Major renal, hepatic or pulmonary disease
  • Major cardiac disease or recent myocardial infarct (\< 6 months)
  • Age less than 18 years
  • Moribund condition on admission (defined as a patient that is in such a poor clinical condition that further active neurosurgical management would not be anticipated)

Key Trial Info

Start Date :

June 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2009

Estimated Enrollment :

327 Patients enrolled

Trial Details

Trial ID

NCT00124150

Start Date

June 1 2002

End Date

June 1 2009

Last Update

December 23 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Surgery, The Chinese University of Hong Kong

Hong Kong, China, 852

Intravenous Magnesium Sulfate in Aneurysmal Subarachnoid Haemorrhage (IMASH) | DecenTrialz